KR20130095286A - 종양 줄기세포에서 eph 수용체의 발현 - Google Patents

종양 줄기세포에서 eph 수용체의 발현 Download PDF

Info

Publication number
KR20130095286A
KR20130095286A KR1020137011310A KR20137011310A KR20130095286A KR 20130095286 A KR20130095286 A KR 20130095286A KR 1020137011310 A KR1020137011310 A KR 1020137011310A KR 20137011310 A KR20137011310 A KR 20137011310A KR 20130095286 A KR20130095286 A KR 20130095286A
Authority
KR
South Korea
Prior art keywords
cells
gbm
epha2
ephrin
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137011310A
Other languages
English (en)
Korean (ko)
Inventor
안젤로 루이지 베스코비
엘레나 빈다
Original Assignee
스템젠 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템젠 에스.피.에이. filed Critical 스템젠 에스.피.에이.
Publication of KR20130095286A publication Critical patent/KR20130095286A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137011310A 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현 Ceased KR20130095286A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10185930.4 2010-10-01
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
PCT/EP2011/067114 WO2012042021A1 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002577A Division KR101719966B1 (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현

Publications (1)

Publication Number Publication Date
KR20130095286A true KR20130095286A (ko) 2013-08-27

Family

ID=43856109

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137011310A Ceased KR20130095286A (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현
KR1020167002577A Active KR101719966B1 (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167002577A Active KR101719966B1 (ko) 2010-10-01 2011-09-30 종양 줄기세포에서 eph 수용체의 발현

Country Status (11)

Country Link
US (1) US9078857B2 (enExample)
EP (2) EP2446895A1 (enExample)
JP (4) JP2013540117A (enExample)
KR (2) KR20130095286A (enExample)
AU (1) AU2011310109B2 (enExample)
CA (1) CA2813101C (enExample)
DK (1) DK2621513T3 (enExample)
ES (1) ES2616444T3 (enExample)
NZ (1) NZ609594A (enExample)
PL (1) PL2621513T3 (enExample)
WO (1) WO2012042021A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302034A1 (en) 2010-12-08 2014-10-09 Stem Centrx, Inc. Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
PT3137114T (pt) 2014-04-30 2021-02-26 Pfizer Conjugados anticorpo-fármaco anti-ptk7
ES2796973T3 (es) 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
CA2985345A1 (en) 2015-05-08 2016-11-17 FlowJo, LLC Data discovery nodes
EP3373939A4 (en) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University MEDIUM AND METHOD FOR REDUCING TUMORIGENITY OF CANCER STEM CELLS
US20240226175A1 (en) * 2020-03-31 2024-07-11 Keio University Therapeutic agent using genome-edited pluripotent stem cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509067A (ja) * 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
AU2005277567A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
BRPI0816094A2 (pt) * 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.

Also Published As

Publication number Publication date
EP2621513B1 (en) 2016-12-28
CA2813101C (en) 2018-10-30
JP2018048151A (ja) 2018-03-29
EP2446895A1 (en) 2012-05-02
US20120083454A1 (en) 2012-04-05
PL2621513T3 (pl) 2017-06-30
CA2813101A1 (en) 2012-04-05
AU2011310109B2 (en) 2014-11-20
JP6618968B2 (ja) 2019-12-11
ES2616444T3 (es) 2017-06-13
JP6523910B2 (ja) 2019-06-05
KR20160027106A (ko) 2016-03-09
AU2011310109A1 (en) 2013-05-02
US9078857B2 (en) 2015-07-14
JP2020037579A (ja) 2020-03-12
NZ609594A (en) 2015-01-30
JP2013540117A (ja) 2013-10-31
EP2621513A1 (en) 2013-08-07
WO2012042021A1 (en) 2012-04-05
JP2016094391A (ja) 2016-05-26
KR101719966B1 (ko) 2017-03-24
DK2621513T3 (en) 2017-03-06

Similar Documents

Publication Publication Date Title
KR101719966B1 (ko) 종양 줄기세포에서 eph 수용체의 발현
Boockvar et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells
JP5891068B2 (ja) Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制
US9730935B2 (en) Targeting a non-canonical notch signaling pathway for cancer treatment
Atherton et al. Sympathetic modulation of tumor necrosis factor alpha-induced nociception in the presence of oral squamous cell carcinoma
WO2012176175A1 (en) New uses of nanog inhibitors and related methods
Schoch et al. Ste20-like kinase is critical for inhibitory synapse maintenance and its deficiency confers a developmental dendritopathy
Fang et al. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions
Jung et al. The role of endothelin receptor A during myelination of developing oligodendrocytes
US20150352114A1 (en) MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS
US20060239988A1 (en) Neuronal regeneration and compound administration methods
Navacci Dissecting the role of the Cullin3-RENKCTD11 E3 ubiquitin ligase complex in the control of the Hedgehog pathway and medulloblastoma tumorigenesis
KR20200028982A (ko) 시냅스 기능을 증진시키기 위한 hdac2-sp3 복합체 표적화
Ludwig Mechanisms of KCC2 upregulation during development
Gomez et al. Aberrant hypothalamic neuronal activity blunts glucocorticoid diurnal rhythms in murine breast cancer
KR20240052739A (ko) 급성 골수성 백혈병 치료를 위한 wnt5a
Tokarew The Role of Norrie Disease Pseudoglioma (Ndp) in Cerebellar Development/Tumorigenesis and Its Relationship with the Sonic Hedgehog Pathway
Lee Molecular Action of a Potential Tumor Suppression in Mammary Carcinogenesis
Comejo et al. Crosstalk between Notch and AKT signaling differentially regulates megakaryocyte development from hematopoietic stem and committed progenitor cells
Wang Jr The Role of ING5 in Maintaining Stemness of Brain Tumor Initiating Cells
Alam Role of the lineage gene Phox2B in neuroblastoma development
Huber The Molecular Role of Non-canonical Notch Signaling Via Deltex-1 in High Grade Glioma
RANGWALA ERBIN MEDIATES SCHWANN CELL GROWTH AND DIFFERENTIATION
Liang Targeting the Notch-1/IGF-1R/Akt Axis in at Orthotopic Model of Advanced Non-Small Cell Lung Cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130430

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130507

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141124

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151028

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141124

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160128

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20151028

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20150526

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130507

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20160224

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160128

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20151028

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150526

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20141124

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20130507